CCI
PTCT icon

Columbus Circle Investors’s PTC Therapeutics PTCT Stock Holding History

Columbus Circle Investors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-20,000
Closed -$400K – 251
2017
Q3 		$400K Buy
+20,000
New +$392K 0.01% 279
2016
Q1 		– Sell
-30,000
Closed -$972K – 302
2015
Q4 		$972K Buy
+30,000
New +$883K 0.01% 254

Other funds holding PTCT

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Columbus Circle Investors's PTCT Position: Q3 2017 in Review

Columbus Circle Investors sold out of PTC Therapeutics (PTCT) in Q3 2017, closing a stake of 12,640 shares — an estimated $247K sold.

Columbus Circle Investors first reported a position in PTCT in Q3 2013 and held it in 12 quarters. The position peaked at $32.5M in Q4 2014. 129 funds tracked by Wall St. Rank hold PTCT as of Q3 2017.

  • Columbus Circle Investors reported no remaining PTC Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Columbus Circle Investors sold 12,640 PTC Therapeutics shares in Q3 2017, an estimated $247K.
  • Columbus Circle Investors first reported a position in PTC Therapeutics in Q3 2013 and held it in 12 quarters.
  • Columbus Circle Investors's PTC Therapeutics position peaked at $32.5M in Q4 2014.
  • 129 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2017.

Based on Columbus Circle Investors's 13F filing for Q3 2017, filed 8 Nov 2017.